REFERENCES
- Petrylak, D.P.; Tangen, C.M.; Hussain, M.N.A. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351, 1513–1520.
- Tannock, I.F.; de Wit, R.; Berry, W.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351, 1502–1512.
- Hill, B.T.; Flebig, H.H.; Waud, W.R. Superior in vivo experimental antitumour activity of vinflunine relative to vinorelbine in a panel of human tumour xenografts. Eur J Cancer 1999, 35, 512–520.
- Culine, S.; Theodore, C.; DeSantis, M. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94, 1395–1414.
- Peacock, N.W.; Spigel, D.R.; Mainwaring, M.G. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2 + patients) as first-line treatment in metastatic breast cancer. J Clin Oncol 2007, 25, 42s (Abstract #1043).
- Krzakowski, M.; Douillard, J.; Ramlau, R. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J Clin Oncol 2007, 25, 387s (Abstract #7511).
- Bubley, G.C.; Carducci, M.; Dahut, W. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17, 3461–3467.
- Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205–216.
- Kaplan, E.L.; Meier, P.; Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457–481.
- Dexeus, F.; Logothetis, C.J.; Samuels, M.L. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985, 69, 885–886.
- Hudes, G.; Einhorn, L.; Ross, E. Vinblastine versus vinplastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase II trial. J Clin Oncol 1999, 17, 3160–3166.
- Caty, A.; Oudard, S.; Humblet, Y. Phase II study of vinorelbine in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997, 16, 311a–
- Carles, J.; Domenech, M.; Gelabert-Mas, A. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncologica 1998, 37, 187–191.